BRISTOL MYERS SQUIBB
Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.
BRISTOL MYERS SQUIBB
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1970
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.bms.com
Total Employee:
10001+
Status:
Active
Contact:
(212)546-4000
Total Funding:
6.08 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome Domain Not Resolving Global Site Tag Nginx
Revenue:
46.16 BTotal Assets:
96.82 BTotal Cash:
9.12 B
Similar Organizations
AccendoWave
AccendoWave provides discomfort detection, monitoring, and reporting devices for the reduction of human suffering.
AmerisourceBergen
AmerisourceBergen provides pharmaceutical supply chain distribution & pharmacy management solutions.
Bartell Drugs
Bartell Drugs is the oldest family owned drugstore chain in the USA.
Dohmen Life Science Service
Intelligent outsourcing for drug and device manufacturers.
Eli Lilly
Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
G. D. Searle
G. D. Searle, LLC is a research-based pharmaceutical company that manufactures and markets prescription pharmaceuticals and other
Gilead Science Korea
Gilead Science Korea is engaged in medical, licensing, marketing, and sales activities.
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.
Johnson & Johnson
Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
KNMP
KNMP is the Royal Dutch Society for the Promotion of Pharmacy is the umbrella professional and branch organization of pharmacists.
Laboratoires Genevrier
Laboratoires Genevrier engages in improving human health by offering an extensive range of innovative and effective pharmaceutical products.
Mayinglong
Mayinglong Pharmaceutical Group manufactures and markets pharmaceutical products.
Medical Products Laboratories
Medical Products is into research, development, manufacturing and distribution of innovative products to our customers.
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Merck
Merck is a pharmaceutical and chemical enterprise that develops prescription drugs and over-the-counter products.
ONO Pharmaceutical
ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents.
Orajel
Orajel engages in the manufacture and marketing of cosmetics and over-the-counter pharmaceuticals.
Pfizer
Pfizer provides access to safe and effective and affordable medicines and health care services.
Pleasant Valley Fund
Pleasant Valley Fund LLC is an early and seed stage investment fund focused on mobile, data, health, biomedical and pharma verticals.
Roxane Laboratories
Roxane Laboratories engages in the research, development, manufacture, marketing, sale, and distribution of generic pharmaceuticals.
Shionogi
Shionogi supply the best possible medicine to protect the health and wellbeing of the patients they serve.
Sustained Nano Systems
Sustained Nano Systems is a company that offers short or long-term micro-dosing for targeting the cell for several therapeutics purposes.
Syndel
For more than 40 years, Syndel has been a leader in developing high quality aquaculture pharmaceutical health and nutritional products.
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
University of California, San Francisco
Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Walgreens
Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
WEPA APOTHEKENBEDARF GmbH & Co KG
WEPA APOTHEKENBEDARF GmbH & Co KG distributes healthcare, laboratory, and formulation equipment and products for pharmacies.
Yliopiston Apteekki
Yliopiston Apteekki is an online store that offers a wide range of medicine, cosmetics, vitamins and nutritional supplements.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Bristol-Myers Squibb Company (BMY)
Last Price
64.44$Change
0.73$ (1.15%)Volume
5.64M| Previous Close | 63.71 |
| Open | 63.69 |
| Day Range | 63.17-64.60 |
| Bid | 0.00 x 1.1k |
| Ask | 0.00 x 800 |
| Volume | 5.64M |
| Average Volume | 7.98M |
| Market Cap | 135.38B |
| Beta | 0.43 |
| 52 Week Range | 63.07-81.44 |
| Trailing P/E | 18.79 |
| Foward P/E | 7.92 |
| Dividend (Yield %) | 3.58% |
| Ex-Dividend Date | 2023-04-06 |
Financial Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-03 | Turning Point Therapeutics | Turning Point Therapeutics acquired by Bristol Myers Squibb | 4.1 B USD |
| 2020-10-05 | MyoKardia | MyoKardia acquired by Bristol Myers Squibb | 13.1 B USD |
| 2020-08-24 | Forbius | Forbius acquired by Bristol Myers Squibb | N/A |
| 2019-11-20 | Celgene | Celgene acquired by Bristol Myers Squibb | N/A |
| 2019-01-03 | Celgene | Celgene acquired by Bristol Myers Squibb | 74 B USD |
| 2017-08-03 | IFM Therapeutics | IFM Therapeutics acquired by Bristol Myers Squibb | N/A |
| 2016-07-05 | Cormorant Pharmaceuticals | Cormorant Pharmaceuticals acquired by Bristol Myers Squibb | N/A |
| 2016-03-23 | Padlock Therapeutics | Padlock Therapeutics acquired by Bristol Myers Squibb | 600 M USD |
| 2015-11-02 | Cardioxyl Pharmaceuticals | Cardioxyl Pharmaceuticals acquired by Bristol Myers Squibb | 2 B USD |
| 2015-02-23 | Flexus Biosciences | Flexus Biosciences acquired by Bristol Myers Squibb | 1.25 B USD |
Investors List
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Bristol Myers Squibb
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Post-IPO Equity - Bristol Myers Squibb
Aperture Venture Partners
Aperture Venture Partners investment in Post-IPO Equity - Bristol Myers Squibb
Greg Bailey
Greg Bailey investment in Post-IPO Equity - Bristol Myers Squibb
Connecticut Innovations
Connecticut Innovations investment in Post-IPO Equity - Bristol Myers Squibb
Knoll Capital Management
Knoll Capital Management investment in Post-IPO Equity - Bristol Myers Squibb
Vivo Capital
Vivo Capital investment in Post-IPO Equity - Bristol Myers Squibb
Venrock
Venrock investment in Post-IPO Equity - Bristol Myers Squibb
Litmore Capital
Litmore Capital investment in Post-IPO Equity - Bristol Myers Squibb
Carl Icahn
Carl Icahn investment in Post-IPO Equity - Bristol Myers Squibb
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-09-08 | Autobahn Therapeutics | Bristol Myers Squibb investment in Venture Round - Autobahn Therapeutics | 32.7 M USD |
| 2022-09-06 | ArsenalBio | Bristol Myers Squibb investment in Series B - ArsenalBio | 220 M USD |
| 2022-08-25 | Aktis Oncology | Bristol Myers Squibb investment in Series A - Aktis Oncology | 84 M USD |
| 2022-07-20 | BigHat Biosciences | Bristol Myers Squibb investment in Series B - BigHat Biosciences | 75 M USD |
| 2022-06-08 | Owkin | Bristol Myers Squibb investment in Series B - Owkin | 50 M USD |
| 2022-06-02 | Transition Bio | Bristol Myers Squibb investment in Series A - Transition Bio | 50 M USD |
| 2022-05-31 | Sapience Therapeutics | Bristol Myers Squibb investment in Series B - Sapience Therapeutics | 41 M USD |
| 2022-05-11 | Nuvig Therapeutics | Bristol Myers Squibb investment in Series A - Nuvig Therapeutics | 47 M USD |
| 2022-04-28 | Octant Bio | Bristol Myers Squibb investment in Series B - Octant Bio | 80 M USD |
| 2022-04-14 | Be Biopharma | Bristol Myers Squibb investment in Series B - Be Biopharma | 130 M USD |
Newest Events participated
Participated in Nordic life science Days 2017
on 2017-09-12 as sponsor
Participated in Fast Company Innovation Festival
on 2016-11-09 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-20 | Novartis-backed ImmPACT Bio snags $111M and new CEO as cancer CAR-T yields phase 1 results |
Official Site Inspections
http://www.bms.com Semrush global rank: 106.06 K Semrush visits lastest month: 919.04 K
- Host name: 165.89.235.99
- IP address: 165.89.235.99
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Bristol Myers Squibb" on Search Engine
Bristol Myers Squibb - Wikipedia
The Bristol-Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.See details»
Bristol Myers Squibb Products & Medicines
For Medical Information, or to Report Side Effects/Adverse Reactions or to Report Product Quality Complaints – please contact Medical Information. 1 866 463-6267. (toll free) …See details»
Bristol-Myers Squibb Medical Information Online for Canada
Bristol-Myers Squibb Medical Information Online for Canada If you are not a healthcare provider please click here. If you are a healthcare provider please click here. To speak …See details»
Annual Report 2022 - Bristol-Myers Squibb
Annual Report 2022 - Bristol-Myers Squibb. “2022 was an important year for our company, one with significant clinical and regulatory achievements that broadened our portfolio, …See details»
Medical Information for Healthcare Providers - Bristol …
Bristol Myers Squibb provides the following information and resources for U.S. healthcare providers (HCPs) to assist with caring for patients and researching innovative medicines. Our medicines > Quick links U.S. …See details»
Company History Timeline - Bristol Myers Squibb
The clinical center at the Bristol-Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, is dedicated to the research and treatment of children’s immune system …See details»
BMY | Bristol Myers Squibb Co. Stock Price & News - WSJ
Bristol Myers Squibb Co. BMY (U.S.: NYSE) REAL TIME 10:27 AM EDT 05/31/23 $64.14USD 0.43 0.67% Volume 971,284 65 Day Avg Vol 7,946,820 1 Day Range 63.15 …See details»
Bristol Myers Squibb Receives Positive CHMP Opinion ... - BioSpace
May 26, 2023 About Bristol Myers Squibb. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative …See details»
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First …
May 25, 2023 Further information is available at www.BreyanziREMS.com, or contact Bristol-Myers Squibb at 1-888-423-5436. Hypersensitivity Reactions Allergic reactions …See details»
Bristol Myers Squibb to Present First Results at ASCO and EHA …
May 25, 2023 PRINCETON, N.J., May 25, 2023--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced first results from the Phase 3 COMMANDS …See details»
Home [www.bmsmedinfo.com]
Welcome to Bristol Myers Squibb’s Medical Information Online Our mission is to empower the healthcare community to make informed decisions about our medicines, …See details»
Contact Us - Bristol Myers Squibb
1-800-721-5072 (toll free U.S. only) Medical Information Contact Center 1-800-321-1335 (toll free U.S. only) Mon - Fri 8am - 8pm ET Patient Support That Speaks Your Language …See details»
Bristol Myers Squibb: Investor Relations
Bristol Myers Squibb Submits Application for Abecma®, a CAR T Cell Therapy, for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least …See details»
Bristol-Myers Squibb Company | American company | Britannica
Bristol-Myers Squibb Company, American biopharmaceutical company resulting from a merger in 1989 and dating to companies founded in 1858 and 1887. It produces …See details»
Bristol Myers Squibb | LinkedIn
Bristol Myers Squibb | 1,035,011 followers on LinkedIn. We discover, develop and deliver innovative medicines that help patients prevail over serious diseases. | At Bristol Myers …See details»
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
May 23, 2023 In the past 30 days, estimates for Novo Nordisk’s 2023 earnings per share have risen from $4.84 to $5.07. Estimates for 2024 have increased by 34 cents to …See details»
Nivolumab (Opdivo) for Hodgkin Lymphoma | FDA
On May 17, 2016, the U. S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo, marketed by Bristol-Myers Squibb) for the treatment of patients with classical Hodgkin ...See details»
Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) is First …
May 25, 2023 Bristol Myers Squibb (NYSE: BMY) today announced the first disclosure of results from the primary analysis of the pivotal TRANSCEND CLL 004 study, a Phase …See details»
Is Bristol Myers Squibb a Top Dividend Stock? | The Motley Fool
5 hours ago Bristol Myers Squibb (BMS) ( BMY 0.96%), a multinational pharmaceutical company, has all the hallmarks of a top-shelf dividend stock. The company has boosted …See details»
Bristol Myers Squibb Enters Oversold Territory (BMY) | Nasdaq
May 26, 2023 In trading on Friday, shares of Bristol Myers Squibb Co. (Symbol: BMY) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as …See details»